SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus - Wikidata - awgldk - TriplyDB

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

http://www.wikidata.org/entity/Q34061012

about

Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma An effective deep-inspiration breath-hold radiotherapy technique for left-breast cancer: impact of post-mastectomy treatment, nodal coverage, and dose schedule on organs at risk.Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.Gastric cancer and the epoch of immunotherapy approaches Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial.An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning.Reversion of the ErbB malignant phenotype and the DNA damage response.Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer.Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1.The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation.The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.Outcomes of nutritional interventions to treat dysphagia in esophageal cancer: a population-based study.

P2860

Q26779221-C3F0A4BD-A7BA-4688-A8C5-69CC8E45EF85 Q28551507-99822377-96CD-4E6F-86E1-F4926C7FD621 Q33812235-B650B878-711D-4120-8EA6-122E115D04D7 Q34844972-8A6B3138-98A3-4997-ADE1-9B63018A4381 Q35085650-F3A02769-85F5-4D75-BCB9-AC951148DEA0 Q35625349-2E487B8B-C6D8-43DE-B05D-94E9165B4D67 Q36055127-2FD10A25-7828-43DD-8C17-DD37F26175E6 Q36287102-EFA4F7B1-E954-4F45-AB3A-BB8359B0E61A Q36553353-E9DA4B54-CEA0-4627-8001-1F1A6C910720 Q36818873-027F75E2-E71A-4711-A00B-FCB268580A6A Q38047648-236ACC8B-A797-47B1-A099-E40A43D34AF2 Q38134835-6DAB7CC9-F46C-4F52-971F-9CD4A59A4BC9 Q38757690-C09625C6-C007-4DD6-9A9A-808A9F583590 Q39115244-2AE9C8DC-32ED-407B-B4D0-4E046FA1E6F2 Q42029319-626F3D5C-3CE8-409D-A24D-82DA469E4307 Q42628995-8D46DF5A-8A11-4D4C-A641-0376487223C1 Q42674196-48EE54F5-DD08-4179-96BE-D87028A3C993 Q45411788-006E94ED-F7DA-480A-9E67-84D2976A8990 Q50205201-B166152B-1473-403E-A2C3-0973C3618494

P2860

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

http://www.wikidata.org/entity/Q34061012

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@ast

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@en

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@nl

type

label

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@ast

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@en

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@nl

prefLabel

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@ast

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@en

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@nl

P1433

Q34061012-3A0DCD8C-8525-4414-A33E-3DD2CA27BF0F

P1476

Q34061012-234E3960-8417-4691-AB06-A765912B2D5A

P2093

Q34061012-1D93D60E-298E-49A8-9B3F-16C5405D626D

Q34061012-27178BF0-DACB-41AD-A2F3-0CE295A7A4A3

Q34061012-2B36E91E-23B9-4AA8-A14C-14253E327AE0

Q34061012-3AE95FCF-CA4D-42E0-A5E7-60D7E565AA3F

Q34061012-4F8E136A-5B63-4722-A80C-F14B9346B334

Q34061012-646BD839-F4DF-41F4-BF8C-B31D31D58A70

Q34061012-F5AE97F2-32E7-470B-87B4-92DAF12AA59A

Q34061012-FFFE982E-334E-4A68-BE7F-BC126007DA11

P2860

Q34061012-09582E17-8200-4934-B956-9A423CF52121

Q34061012-0A243E94-84D5-4CB7-885D-691DB5C19A58

Q34061012-0F937B00-52FB-4342-AA46-B9A75EA050B6

Q34061012-11D952BE-F936-45D4-ADFF-DFF24359E47A

Q34061012-1D952C6C-2C1E-479E-B6EB-F578B55F0163

Q34061012-21832BC9-EBA2-41E2-8C1C-FF9DCD0EFC28

Q34061012-21CE6B4C-7AC5-41FD-A47C-242A4F1245E3

Q34061012-22DBC16A-0C05-414E-A162-E28D7501C296

Q34061012-34F8E0EE-63E9-4908-8B62-CDC10B003C13

Q34061012-4384AD23-C507-4509-A8FF-69ECDA9054E2

P2888

Q34061012-0473193B-492C-4560-8847-47EA5DA5602C

P304

Q34061012-4EEF1A60-8659-43B3-A624-3A318C63B00C

P31

Q34061012-AB358405-F389-4A4B-B179-D2301627ABCB

P356

Q34061012-97F4CB17-7AAC-4BC9-8E3F-75BA4CDAD7E0

P407

Q34061012-CBDAF311-B6C3-4472-A70E-B246901415CA

P478

Q34061012-A371CFCD-F157-46EC-BE17-FB405A85573B

P50

Q34061012-3278335A-977F-4875-843A-D6F5F77DA486

P577

Q34061012-AD7CB546-F46E-49B7-882D-B0999F6E7F80

P5875

Q34061012-6423DAA6-E70D-41DC-81E1-85A415020444

P6179

Q34061012-9286AB0E-08D2-4745-A3AE-1D506C33D52D

P698

Q34061012-0B7AE927-7993-4997-A51D-337885ECB7BF

P921

Q34061012-3053CF14-A555-488D-A39B-50866E5209D7

Q34061012-626DA243-586F-48A4-8D46-F26A6FAD1554

Q34061012-72946EFE-D36E-4D65-BDF1-258C725AC2BC

Q34061012-9C70C281-1EFA-4BDC-9093-37618A46F87A

Q34061012-F6D276B5-E779-4E84-A676-25039A0BAB78

P932

Q34061012-8100D67D-DE95-4E24-A93E-F78E42648736

P356

1471-2407-11-466

P1433

P1476

SCOPE1: a randomised phase II/ ...... in carcinoma of the oesophagus

@en

P2093

Christopher N Hurt

http://www.w3.org/2001/XMLSchema#string

Gareth O Griffiths

http://www.w3.org/2001/XMLSchema#string

Jane M Blazeby

http://www.w3.org/2001/XMLSchema#string

John N Staffurth

http://www.w3.org/2001/XMLSchema#string

Lisette S Nixon

http://www.w3.org/2001/XMLSchema#string

Ruby Al-Mokhtar

http://www.w3.org/2001/XMLSchema#string

Simon Gollins

http://www.w3.org/2001/XMLSchema#string

Tom D Crosby

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Chemoradiotherapy of esophageal carcinoma.

The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324

Relapse patterns after chemo-radiation for carcinoma of the oesophagus.

10 years experience of the Dermatology Life Quality Index (DLQI).

P2888

1471-2407-11-466

P304

466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-466

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51754897

http://www.w3.org/2001/XMLSchema#string

P6179

1028647114

http://www.w3.org/2001/XMLSchema#string

P698

22035459

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial

chemoradiotherapy

multicenter trial

P932

3212828

http://www.w3.org/2001/XMLSchema#string